Geistlich Pharma highlights solid progress during 2013

Geistlich Pharma has published a review of its business performance during 2013, during which it posted solid growth despite a difficult trading environment.

Although economic pressures continued to impact the healthcare sector last year, the firm strengthened or expanded its position in most of its markets, with its dental, orthopaedics and medical units all achieving forward momentum.

Its turnover rose compared to the previous year, with a growth rate in the high single-digit range, thanks to a balanced geographical mix, an attractive product pipeline and the operational strength of the company.

The launches of products such as Geistlich Mucograft Seal, Geistlich Bio-Gide, AMIC Hip and Chondro-Gide in key territories helped to drive these sales.

A statement said: "Geistlich Pharma is expecting a market environment that will continue to be challenging. The company is also well positioned for the challenges in the new year and is looking forward to successfully tackling these too."

Geistlich Pharma's corporate history dates back to 1851. Currently, it serves customers in more than 50 countries worldwide.